Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

The Incidence of Chiari Malformations in Patients with Isolated Sagittal Synostosis.

Davis AA, Zuccoli G, Haredy MM, Runkel L, Losee J, Pollack IF, Tamber MS, Tyler-Kabara E, Goldstein JA, Nischal KK.

Plast Reconstr Surg Glob Open. 2019 Feb 12;7(2):e2090. doi: 10.1097/GOX.0000000000002090. eCollection 2019 Feb.

2.

Costimulatory pathway targets for autoimmune and inflammatory conditions: clinical successes, failures, and hope for the future.

Spicer P, Runkel L.

Expert Opin Investig Drugs. 2019 Feb;28(2):99-106. doi: 10.1080/13543784.2019.1557146. No abstract available.

PMID:
30661473
3.

Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?

Runkel L, Stacey J.

Expert Opin Biol Ther. 2014 Apr;14(4):491-501. doi: 10.1517/14712598.2014.884065. Epub 2014 Feb 3. Review.

PMID:
24490627
4.

TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis.

Dohi T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, Runkel L, Rajman L, Dong X, Scott ML, Michaelson JS, Jakubowski A, Burkly LC.

Gastroenterology. 2009 Mar;136(3):912-23. doi: 10.1053/j.gastro.2008.11.017. Epub 2008 Nov 8.

PMID:
19109961
5.

TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model.

Iocca HA, Plant SR, Wang Y, Runkel L, O'Connor BP, Lundsmith ET, Hahm K, van Deventer HW, Burkly LC, Ting JP.

J Neuroimmunol. 2008 Feb;194(1-2):97-106. doi: 10.1016/j.jneuroim.2007.12.003. Epub 2008 Jan 18.

PMID:
18207576
6.

IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration.

Avraamides G, Ng CY, David R, Gu Y, Fazekasova H, Mirenda V, Foster GR, Runkel L, Lombardi G, Marelli-Berg FM.

J Interferon Cytokine Res. 2007 Apr;27(4):291-303.

PMID:
17477817
7.

TWEAK is a novel arthritogenic mediator.

Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H.

J Immunol. 2006 Aug 15;177(4):2610-20.

8.

Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis.

Runkel L, De Dios C, Karpusas M, Baker D, Li Z, Zafari M, Betzenhauser M, Muldowney C, Miller S, Redlich PN, Grossberg SE, Whitty A, Hochman PS.

J Interferon Cytokine Res. 2001 Nov;21(11):931-41.

PMID:
11747625
9.

Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A.

Schneider P, Street SL, Gaide O, Hertig S, Tardivel A, Tschopp J, Runkel L, Alevizopoulos K, Ferguson BM, Zonana J.

J Biol Chem. 2001 Jun 1;276(22):18819-27. Epub 2001 Mar 14.

10.

Isolation and characterization of cDNAs for the protein kinase HIPK2.

Wang Y, Hofmann TG, Runkel L, Haaf T, Schaller H, Debatin K, Hug H.

Biochim Biophys Acta. 2001 Mar 19;1518(1-2):168-72.

PMID:
11267674
11.

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.

Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS, Whitty A.

Biochemistry. 2000 Mar 14;39(10):2538-51.

PMID:
10704203
12.

Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.

Arduini RM, Strauch KL, Runkel LA, Carlson MM, Hronowski X, Foley SF, Young CN, Cheng W, Hochman PS, Baker DP.

Protein Sci. 1999 Sep;8(9):1867-77.

13.

Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis.

Goldman LA, Zafari M, Cutrone EC, Dang A, Brickelmeier M, Runkel L, Benjamin CD, Ling LE, Langer JA.

J Interferon Cytokine Res. 1999 Jan;19(1):15-26.

PMID:
10048764
14.

The structure of human interferon-beta: implications for activity.

Karpusas M, Whitty A, Runkel L, Hochman P.

Cell Mol Life Sci. 1998 Nov;54(11):1203-16. Review.

PMID:
9849615
15.

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, Brickelmaier M, Muldowney C, Jones W, Goelz SE.

Pharm Res. 1998 Apr;15(4):641-9.

PMID:
9587963
16.

Differences in activity between alpha and beta type I interferons explored by mutational analysis.

Runkel L, Pfeffer L, Lewerenz M, Monneron D, Yang CH, Murti A, Pellegrini S, Goelz S, Uzé G, Mogensen K.

J Biol Chem. 1998 Apr 3;273(14):8003-8.

17.

Interferon-beta induces S phase accumulation selectively in human transformed cells.

Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J.

J Interferon Cytokine Res. 1997 Jun;17(6):355-67.

PMID:
9198003
18.

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L.

J Exp Med. 1995 Nov 1;182(5):1223-30.

19.
20.

Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.

Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3764-8.

21.
22.

Multiple basal promoter elements determine the level of human c-fos transcription.

Runkel L, Shaw PE, Herrera RE, Hipskind RA, Nordheim A.

Mol Cell Biol. 1991 Mar;11(3):1270-80.

23.
25.

Supplemental Content

Loading ...
Support Center